Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum-derived extracellular vesicles
- Development stage
- Preclinical
- Lead developer
- Ewha Womans University
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intraperitoneal, Intracerebral
01
Overview
Lactobacillus plantarum-derived extracellular vesicles (L-EVs) are nano-sized, membrane-bound vesicles naturally secreted by the probiotic bacterium *Lactobacillus plantarum*. These vesicles act as key mediators in the gut-brain axis, facilitating communication between the intestinal microbiota and the central nervous system. Research indicates that L-EVs possess therapeutic potential for treating Alcohol Use Disorder (AUD) by modulating neurobiological pathways associated with addiction. Specifically, administration of L-EVs has been shown to reduce alcohol consumption and withdrawal-related behaviors in animal models by enhancing the expression of Brain-Derived Neurotrophic Factor (BDNF) in the ventral tegmental area (VTA). This effect is mediated through the activation of the TrkB signaling pathway. Additionally, L-EVs may help restore intestinal barrier integrity and normalize gut microbiota composition, which are often compromised by chronic alcohol consumption.
- Other names
- Lactobacillus plantarum extracellular vesiclesL. plantarum EVs
02
Targets
NTRK2 (Tropomyosin-related kinase receptor type B)BDNF (Brain-derived neurotrophic factor)
Beyond the preview
Go deeper on lactobacillus plantarum-derived extracellular vesicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum-derived extracellular vesicles.